Suppr超能文献

中度至重度活动性格雷夫斯眼眶病类固醇治疗后生活质量变化的预测因素:一项前瞻性试验

Predictive Factors for Changes in Quality of Life after Steroid Treatment for Active Moderate-to-Severe Graves' Orbitopathy: A Prospective Trial.

作者信息

Hoppe Elena, Lee Alan Chun Hong, Hoppe David, Kahaly George J

机构信息

Department of Medicine I, Johannes Gutenberg University Medical Center, Mainz, Germany.

Department of Paediatrics, Johannes Gutenberg University Medical Center, Mainz, Germany.

出版信息

Eur Thyroid J. 2021 Feb;9(6):313-320. doi: 10.1159/000508071. Epub 2020 Jul 2.

Abstract

OBJECTIVES

To investigate the predictive factors for changes in the quality of life (GO-QoL) of patients with Graves' orbitopathy (GO) prior to and after specific treatment.

METHODS

A prospective follow-up study was conducted at an academic tertiary referral orbital center with a joint thyroid-eye clinic on 100 consecutive patients with GO. Before and after the standard 12-week course of weekly intravenous methylprednisolone (cumulative dose 4.5 g), the GO-QoL questionnaire provided by the European Group on Graves' Orbitopathy (EUGOGO) was completed. Endocrine and ophthalmic assessments were performed at each visit.

RESULTS

All patients were biochemically euthyroid and untreated for GO at baseline and presented with active and moderate-to-severe disease. Both GO-QoL subscales (visual functioning [VF] and appearance [AP]) significantly increased after immunosuppressive therapy and showed a sustained improvement for 6 months. At baseline, demographic variables (sex, age, and smoking) influenced QoL in the stepwise linear regression ( < 0.01, adjusted = 0.24 for VF and < 0.01, adjusted = 0.21 for AP). In contrast, 6 months after treatment, the improved QoL was now exclusively associated with ophthalmic parameters ( < 0.01, adjusted = 0.47 for VF; < 0.01, adjusted = 0.23 for AP).

CONCLUSIONS

Predictive factors for GO-QoL differed not only between the 2 subscales but also before and after the first treatment of GO.

摘要

目的

研究格雷夫斯眼眶病(GO)患者在特定治疗前后生活质量变化(GO-QoL)的预测因素。

方法

在一家学术性三级转诊眼眶中心与甲状腺-眼科联合诊所对100例连续的GO患者进行前瞻性随访研究。在每周静脉注射甲泼尼龙标准12周疗程(累积剂量4.5 g)前后,完成欧洲格雷夫斯眼眶病专家组(EUGOGO)提供的GO-QoL问卷。每次就诊时进行内分泌和眼科评估。

结果

所有患者在基线时生化指标甲状腺功能正常且未接受GO治疗,表现为活动性中重度疾病。免疫抑制治疗后,GO-QoL的两个子量表(视觉功能[VF]和外观[AP])均显著提高,并在6个月内持续改善。在基线时,人口统计学变量(性别、年龄和吸烟)在逐步线性回归中影响生活质量(VF:<0.01,调整后R² = 0.24;AP:<0.01,调整后R² = 0.21)。相比之下,治疗6个月后,改善的生活质量仅与眼科参数相关(VF:<0.01,调整后R² = 0.47;AP:<0.01,调整后R² = 0.23)。

结论

GO-QoL的预测因素不仅在两个子量表之间不同,而且在GO首次治疗前后也不同。

相似文献

2
[Evaluation of quality of life in patients with Graves orbitopathy and its influencing factors].
Zhonghua Nei Ke Za Zhi. 2019 Aug 1;58(8):577-583. doi: 10.3760/cma.j.issn.0578-1426.2019.08.006.
3
Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients.
Front Endocrinol (Lausanne). 2019 Apr 4;10:192. doi: 10.3389/fendo.2019.00192. eCollection 2019.
6
Evaluation of the Graves' Orbitopathy-Specific Quality of Life Questionnaire in the Mainland Chinese Population.
J Ophthalmol. 2019 Mar 18;2019:7602419. doi: 10.1155/2019/7602419. eCollection 2019.
8
Objective and subjective outcomes of strabismus surgery in Graves' orbitopathy: a prospective multicentre study.
Acta Ophthalmol. 2017 Jun;95(4):386-391. doi: 10.1111/aos.13367. Epub 2017 Jan 30.
9
The Effect of Ophthalmic Surgery for Graves' Orbitopathy on Quality of Life: A Systematic Review and Meta-Analysis.
Thyroid. 2022 Feb;32(2):177-187. doi: 10.1089/thy.2021.0411. Epub 2022 Jan 25.
10
Quality of life of patients with thyroid eye disease: 3-year follow-up in a multidisciplinary clinic in Israel.
Graefes Arch Clin Exp Ophthalmol. 2021 Jul;259(7):2009-2015. doi: 10.1007/s00417-021-05103-5. Epub 2021 Feb 2.

引用本文的文献

2
The burden of illness in thyroid eye disease: current state of the evidence.
Front Ophthalmol (Lausanne). 2025 Apr 17;5:1565762. doi: 10.3389/fopht.2025.1565762. eCollection 2025.
3
Teprotumumab Improves Quality of Life in Thyroid Eye Disease: Meta-analysis and Matching-adjusted Indirect Comparison.
J Endocr Soc. 2025 Apr 8;9(6):bvaf063. doi: 10.1210/jendso/bvaf063. eCollection 2025 Jun.
4
5
Graves' ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions - a systematic review.
BMJ Open Ophthalmol. 2024 Jun 17;9(1):e001515. doi: 10.1136/bmjophth-2023-001515.
7
Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience.
Pharmacol Rep. 2024 Feb;76(1):185-194. doi: 10.1007/s43440-023-00567-0. Epub 2024 Jan 26.
8
Selenium in the treatment of mild-to-moderate Graves' orbitopathy: a 5-year prospective controlled cohort study.
Endocrine. 2024 Jun;84(3):1072-1080. doi: 10.1007/s12020-023-03672-5. Epub 2024 Jan 10.
9
Comparison of the efficacy of two different glucocorticoid regimens for treatment of active moderate-to-severe Graves' orbitopathy.
Int Ophthalmol. 2023 Dec;43(12):4747-4757. doi: 10.1007/s10792-023-02875-z. Epub 2023 Sep 12.
10
Traditional Chinese medicine in thyroid-associated orbitopathy.
J Endocrinol Invest. 2023 Jun;46(6):1103-1113. doi: 10.1007/s40618-023-02024-4. Epub 2023 Feb 12.

本文引用的文献

1
Quality of Life in Thyroid Eye Disease: A Systematic Review.
Ophthalmic Plast Reconstr Surg. 2020 Mar/Apr;36(2):118-126. doi: 10.1097/IOP.0000000000001446.
2
Immunohistochemical analysis of human orbital tissue in Graves' orbitopathy.
J Endocrinol Invest. 2020 Feb;43(2):123-137. doi: 10.1007/s40618-019-01116-4. Epub 2019 Sep 19.
3
[Evaluation of quality of life in patients with Graves orbitopathy and its influencing factors].
Zhonghua Nei Ke Za Zhi. 2019 Aug 1;58(8):577-583. doi: 10.3760/cma.j.issn.0578-1426.2019.08.006.
4
Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients.
Front Endocrinol (Lausanne). 2019 Apr 4;10:192. doi: 10.3389/fendo.2019.00192. eCollection 2019.
5
Evaluation of the Graves' Orbitopathy-Specific Quality of Life Questionnaire in the Mainland Chinese Population.
J Ophthalmol. 2019 Mar 18;2019:7602419. doi: 10.1155/2019/7602419. eCollection 2019.
6
High Titers of Thyrotropin Receptor Antibodies Are Associated With Orbitopathy in Patients With Graves Disease.
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2561-2568. doi: 10.1210/jc.2018-02705.
7
2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.
Eur Thyroid J. 2018 Aug;7(4):167-186. doi: 10.1159/000490384. Epub 2018 Jul 25.
8
The relationship between quality of life, cognition, and thyroid status in Graves' disease.
Endocrine. 2019 Jan;63(1):87-93. doi: 10.1007/s12020-018-1733-y. Epub 2018 Sep 1.
9
Quality of life and neuropsychiatric disorders in patients with Graves' Orbitopathy: Current concepts.
Autoimmun Rev. 2018 Jul;17(7):639-643. doi: 10.1016/j.autrev.2017.12.012. Epub 2018 May 2.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验